Dr. Lipika Goyal, MD

Dr. Goyal practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Goyal's NPI, 1720287055, was assigned on July 17, 2007. Dr. Goyal graduated from Harvard Medical School in 2007. Dr. Goyal holds California license C184275.

Dr. Goyal's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Goyal's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Goyal to 1 more hospital and 1 medical group, each named with a free account. Dr. Goyal's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goyal practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Goyal's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Goyal is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Goyal's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists multiple myeloma and prostate cancer among the conditions Dr. Goyal treats.

CMS data shows 306 Medicare services from Dr. Goyal across 6 procedure codes in 2024, for 60 Medicare patients. Medicare paid $25,223 for them.

CMS counts 60 Medicare patients who saw Dr. Goyal in 2024. The largest group is 65 to 74, with 31 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 30% are also on Medicaid. Their average risk score is 3.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goyal's median patient age at 63, with 47% women.

In 2024, Dr. Goyal wrote 55 Medicare Part D claims for 20 patients. 89% of them were for generic drugs. CMS names the drug for 27 of them, across 2 drugs with 11 or more claims each, at $113 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Goyal for performance year 2024, reported as part of a group. Dr. Goyal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goyal as offering telehealth.

Dmand AI links 124 papers to Dr. Goyal, published from 2013 to 2025. 2020 was the busiest year, with 16. The most frequent topics are Cholangiocarcinoma, Bile Duct Neoplasms and Liver Neoplasms. Dr. Goyal has published most often in Clin Cancer Res. Dr. Goyal's most frequent co-authors are Lawrence Scott Blaszkowsky, MD, Jennifer Y. Wo, MD and Jeffrey William Clark, MD.

Dmand AI links Dr. Goyal to 7 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Bile Duct Neoplasms, Biliary Tract Neoplasms and Gallbladder Neoplasms. Open Payments lists research payments to Dr. Goyal that name 2 trials.

CMS Open Payments shows 137 general payments to Dr. Goyal from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. Taiho Oncology, Inc. paid the most, $50,792. It also lists 5 research payments totaling $9,536 from 2017 to 2021, naming 2 clinical trials.

Dr. Goyal graduated from Harvard Medical School in 2007.

Dr. Goyal is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Massachusetts. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.